On June 5, 2025 Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, reported the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells (Press release, Mission Bio, JUN 5, 2025, View Source [SID1234653751]). The assay, which can be leveraged for Phase 2 or 3 trials to home in on patients most likely to benefit from a cancer therapy, will be unveiled at the European Hematology Association (EHA) (Free EHA Whitepaper) meeting in Milan, Italy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Single-Cell Genotype and Targeted Gene Expression is available through Mission Bio’s Pharma Assay Development (PAD) services, where the company’s experts provide end-to-end support from custom single-cell assay design and development to data interpretation and assay transfer. The multi-modal assay has three primary applications: helping understand therapeutic resistance, designing next-generation T-cell therapies, and improving patient selection in clinical development.
In particular, the Single-Cell Genotype and Targeted Gene Expression assay addresses critical challenges in oncology drug development, where obtaining the complete picture of tumor heterogeneity and therapeutic resistance mechanisms has been hampered by limitations in existing and disparate methods. By capturing both genomic mutations and targeted gene expression changes in the same cell, the enhanced Tapestri Platform enables pharmaceutical researchers to gain a comprehensive, high-resolution view of cancer cell behavior and treatment response – allowing companies to derisk late-stage development.
"The majority of clinical failures in hematologic cancer drug development occur in Phases II and III, often due to inadequate patient response and lack of predictive biomarkers for patient stratification," said Brian Kim, CEO of Mission Bio. "We’re directly addressing the urgent need to understand which patients will respond to which drugs at what time, by adding this custom capability to our portfolio of tools. It builds on our continuing mission to offer the tools that drug developers need to understand drug impact at the single-cell level and de-risk late-stage clinical trial failures."
The new Single-Cell Genotype and Targeted Gene Expression assay also features sample multiplexing capabilities, reducing the cost of single-cell analysis by approximately 60% compared to using multiple technologies to generate similar insights. Tapestri users have previously developed bespoke capabilities to leverage targeted gene expression alongside single-cell genotype and multi-omics, an early demonstration of the value of Mission Bio’s newly integrated approach. Among multiple use cases has been the deconvolution of clonal architecture and tracking resistant subclones under therapeutic pressure in AML. In the future, Mission Bio’s PAD team will enable true multi-omics by adding immunophenotyping to the Single-Cell Genotype and Targeted Gene Expression assay.
Mission Bio and Partners Presenting at EHA (Free EHA Whitepaper)
EHA will feature two oral presentations from Mission Bio’s academic partners featuring use of the Tapestri Platform.
Interrogating clonal evolution of NPM1-mutant AML through genetic and genomic approaches
Dr. Linde Miles, assistant professor at Cincinnati Children’s Hospital Medical Center
Friday, 13 June, 15:45 – 16:15 CEST
Amber Hall 7+8
Session 3 Keynote lecture: Cell fate and cell plasticity in normal and malignant hematopoiesis
Dr. Lars Velten, Centre for Genomic Regulation (CRG) Barcelona, Spain
Saturday, 14 June, 14:00 – 14:20 CEST
Brown Hall 2
Both Dr. Miles and Dr. Velton will also present at Mission Bio’s EHA (Free EHA Whitepaper) evening event, The Power of One: A Night of Multi-Omics Discovery @ EHA (Free EHA Whitepaper) 2025, Friday, June 13, 2025 at 7:00 PM.
Late-Breaking Oral Session: INCA33989 is a Novel, First In Class, Mutant Calreticulin-Specific Monoclonal Antibody that Demonstrates Safety and Efficacy in Patients with Essential Thrombocythemia (ET)
Dr. John Mascarenhas, Icahn School of Medicine at Mount Sinai
Sunday, June 15, 2025, 09:15 CEST
Location TBD
Mission Bio will also be presenting six posters at EHA (Free EHA Whitepaper) in Poster Hall, beginning on Saturday, 14 June, 18:30 CEST.
CXCR4 Expression In Aml Blasts And Its Impact On CXCR4 Inhibitor Efficacy During Consolidation Therapy: Results From The Sal Blast Trial
Dr. Enise Ceran (Heidelberg, Germany)
Single Cell Multi-omic Analysis Uncovers Molecular And Clonal Events Associated With Ruxolitinib Treatment Response In Myelofibrosis
Dr. Sebastiano Rontauroli (Modena, Italy)
Characterization Of CD9 As A Novel Marker For Disease-Propagating Stem Cells In Myelofibrosis
Dr. Lara Tavernari (Modena, Italy)
Deciphering Clonal Heterogeneity In Aml Npm1 Through Single-Cell Multi-Omic
Dr. Wencke Walter (Munich, Germany)
Three Patterns Of Molecular Minimal Residual Disease Kinetics In Venetoclax + Azacitidine (V+A) Treated Acute Myeloid Leukemia (AML) Patients
Dr. Jiří Mayer (Brno, Czechia)
High-Throughput And Highly Sensitive Single Cell Genotyping With Simultaneous Chromatin Accessibility Profiling In Myeloid Precursor Conditions
Dr. Masanori Motomura (Kyoto, Japan)
For more information about Mission Bio’s Targeted Single-Cell Gene Expression assay and Pharma Assay Development services, please visit missionbio.com.
Visit Mission Bio at EHA (Free EHA Whitepaper) at booth M.10.